North Dakota legislation · 69th Legislative Assembly
North Dakota SB2370: AN ACT to provide for a legislative management study regarding prescription drug transparency reporting under the federal drug discount program.
Status: Signed into law, June 11, 2025
What the bill says
An act to provide for a legislative management study regarding prescription drug transparency reporting under the federal drug discount program.
From the enrolled text, May 1, 2025:
AN ACT to provide for a legislative management study regarding prescription drug transparency reporting under the federal drug discount program. SECTION 1. LEGISLATIVE MANAGEMENT STUDY - PRESCRIPTION DRUG TRANSPARENCY REPORTING. 1. During the 2025-26 interim, the legislative management shall study establishing reporting requirements for covered entities in North Dakota which participate in the federal drug discount program under 42 U.S.C. 256b, and how reported data could be used to develop public policy that directly benefits patients in North Dakota. 2. The study must include: a. Consideration of the various entities participating in the federal drug discount program that should be required to report data to this state, including health care facilities, contract pharmacies, federally qualified health centers, drug manufacturers, pharmacy benefits managers, and health insurers. b. Consideration of the specific data elements that each entity should be required to report. c. Exploration of methods of reporting, compiling, and sharing the compiled data which provide the greatest benefit to patients in North Dakota. d. Analysis of issues relating to the confidentiality and disclosure of the data. e. Consideration of reporting enforcement mechanisms, including civil penalties for failing to report. f. Input from and consultation with stakeholders, including: (1) A professional association representing hospitals in North Dakota. (2) A professional association representing pharmacies in North Dakota. (3) A professional association representing federally …
Sponsors
- Sean Cleary (R, 35) · primary sponsor
- Dick Dever (R, 32)
- Tim Mathern (D, 11)
- Carrie McLeod (R, 45)
Latest actions
- : Filed with Secretary Of State 05/02
- : Signed by Governor 05/02
- : Sent to Governor
- : Signed by President
- : Signed by Speaker
- : Second reading, passed as amended, yeas 77 nays 12
- : Conference committee report adopted
- : Second reading, passed, yeas 40 nays 5
- : Conference committee report adopted
- : Reported back from conference committee, in place of, placed on calendar
Votes
- Final Passage (April 28, 2025): 77 yea, 12 nay, passed
- Final Passage (April 25, 2025): 40 yea, 5 nay, passed
- Final Passage (April 17, 2025): 65 yea, 27 nay, passed
- Final Passage (February 24, 2025): 47 yea, 0 nay, passed
Common questions
- What is SB2370?
- SB2370 is a bill in the North Dakota Legislature (69th Legislative Assembly): AN ACT to provide for a legislative management study regarding prescription drug transparency reporting under the federal drug discount program.
- What does SB2370 do?
- In its own words: An act to provide for a legislative management study regarding prescription drug transparency reporting under the federal drug discount program.
- What is the status of SB2370?
- Signed into law as of June 11, 2025. Latest action: Filed with Secretary Of State 05/02 (June 11, 2025).
- Who sponsored SB2370?
- Sean Cleary (R, 35), with 3 co-sponsors.
- Where is the official record for SB2370?
- On the North Dakota Legislature website: https://ndlegis.gov/assembly/69-2025/regular/bill-overview/bo2370.html
Source: official North Dakota record. Tracked by Delilah, AI for legislation across all 50 states and Congress.